TISSUE REGENIX GROUP Business Summary

Tissue Regenix Group PLC (TRX) is a regenerative medicine specialist that generates revenue through the commercialization of proprietary tissue-scaffold technologies, primarily dCELL (decellularization of human and animal soft tissue) and BioRinse (bone allograft processing). The company operates across three primary business segments: BioRinse (orthopedics and dental bone grafts), dCELL (wound care and sports medicine), and third-party tissue processing partnerships. Revenue is derived from a hybrid model of direct sales to hospitals and surgical centers and strategic distribution agreements with global medical device partners. As of February 2026, the company has transitioned from the London Stock Exchange (AIM) to the Asset Match private market following a 2025 financial restructuring and "strategic restart" aimed at stabilizing its cost base. TRX competes directly with larger industry players such as Organogenesis Holdings, RTI Surgical, AlloSource, and MTF Biologics; it maintains a niche position by leveraging its patented decellularization process to provide acellular scaffolds that minimize immune rejection while supporting natural tissue regeneration. Originally founded in 2006 as a spin-out from the University of Leeds, the company was built on the research of co-founders Professor Eileen Ingham, an immunologist, and Professor John Fisher, a bioengineer. The current leadership team is led by Executive Chairman and acting CEO Jay LeCoque, who brings over 25 years of experience from senior roles at Source BioScience and Celsis International. He is supported by CFO Kirsten Lund, a long-term veteran of the group reappointed in late 2025 to oversee financial recovery, and COO Judy Madden, who previously held executive positions at Charles River Laboratories. The company’s board and strategic direction are significantly influenced by major institutional investors, including Harwood Capital, IP Group, and Aquarius Equity Partners, who recently participated in emergency funding rounds to support the firm's ongoing commercial operations and geographic expansion into European and Asian markets.